Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Published

Journal Article

BACKGROUND: Clade B DNA and recombinant modified vaccinia Ankara (MVA) vaccines producing virus-like particles displaying trimeric membrane-bound envelope glycoprotein (Env) were tested in a phase 2a trial in human immunodeficiency virus (HIV)-uninfected adults for safety, immunogenicity, and 6-month durability of immune responses. METHODS: A total of 299 individuals received 2 doses of JS7 DNA vaccine and 2 doses of MVA/HIV62B at 0, 2, 4, and 6 months, respectively (the DDMM regimen); 3 doses of MVA/HIV62B at 0, 2, and 6 months (the MMM regimen); or placebo injections. RESULTS: At peak response, 93.2% of the DDMM group and 98.4% of the MMM group had binding antibodies for Env. These binding antibodies were more frequent and of higher magnitude for the transmembrane subunit (gp41) than the receptor-binding subunit (gp120) of Env. For both regimens, response rates were higher for CD4(+) T cells (66.4% in the DDMM group and 43.1% in the MMM group) than for CD8(+) T cells (21.8% in the DDMM group and 14.9% in the MMM group). Responding CD4(+) and CD8(+) T cells were biased toward Gag, and >70% produced 2 or 3 of the 4 cytokines evaluated (ie, interferon γ, interleukin 2, tumor necrosis factor α, and granzyme B). Six months after vaccination, the magnitudes of antibodies and T-cell responses had decreased by <3-fold. CONCLUSIONS: DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durable antibody and T-cell responses.

Full Text

Duke Authors

Cited Authors

  • Goepfert, PA; Elizaga, ML; Seaton, K; Tomaras, GD; Montefiori, DC; Sato, A; Hural, J; DeRosa, SC; Kalams, SA; McElrath, MJ; Keefer, MC; Baden, LR; Lama, JR; Sanchez, J; Mulligan, MJ; Buchbinder, SP; Hammer, SM; Koblin, BA; Pensiero, M; Butler, C; Moss, B; Robinson, HL; HVTN 205 Study Group, ; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network,

Published Date

  • July 1, 2014

Published In

Volume / Issue

  • 210 / 1

Start / End Page

  • 99 - 110

PubMed ID

  • 24403557

Pubmed Central ID

  • 24403557

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiu003

Language

  • eng

Conference Location

  • United States